{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/dinutuximab",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709444",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709444_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"anti-D (Rh0) immunoglobulin\" outputclass=\"int-drug\">Anti-D (Rh0) immunoglobulin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">alter</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Anti-D (Rh0) immunoglobulin   is predicted to   alter   the effects of   dinutuximab .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anti-D (Rh0) immunoglobulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709445",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709445_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"antithymocyte immunoglobulin (rabbit)\" outputclass=\"int-drug\">Antithymocyte immunoglobulin (rabbit)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">alter</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Antithymocyte immunoglobulin (rabbit)   is predicted to   alter   the effects of   dinutuximab .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Antithymocyte immunoglobulin (rabbit)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709446",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709446_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"Bacillus Calmette-Guérin vaccine\" outputclass=\"int-drug\">Bacillus Calmette-Guérin vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bacillus Calmette-Guérin vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   dinutuximab .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bacillus Calmette-Guérin vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709447",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709447_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"beclometasone\" outputclass=\"int-drug\">Beclometasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of immunosuppression when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid except in life-threatening situations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Beclometasone   is predicted to   increase   the risk of immunosuppression when given with   dinutuximab .  Manufacturer advises avoid except in life-threatening situations .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Beclometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709448",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709448_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"betamethasone\" outputclass=\"int-drug\">Betamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of immunosuppression when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid except in life-threatening situations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Betamethasone   is predicted to   increase   the risk of immunosuppression when given with   dinutuximab .  Manufacturer advises avoid except in life-threatening situations .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709449",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709449_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"budesonide\" outputclass=\"int-drug\">Budesonide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of immunosuppression when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid except in life-threatening situations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Budesonide   is predicted to   increase   the risk of immunosuppression when given with   dinutuximab .  Manufacturer advises avoid except in life-threatening situations .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Budesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709450",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709450_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ciclesonide\" outputclass=\"int-drug\">Ciclesonide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of immunosuppression when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid except in life-threatening situations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ciclesonide   is predicted to   increase   the risk of immunosuppression when given with   dinutuximab .  Manufacturer advises avoid except in life-threatening situations .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709451",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709451_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of immunosuppression when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid except in life-threatening situations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   increase   the risk of immunosuppression when given with   dinutuximab .  Manufacturer advises avoid except in life-threatening situations .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deflazacort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709452",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709452_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dexamethasone\" outputclass=\"int-drug\">Dexamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of immunosuppression when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid except in life-threatening situations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dexamethasone   is predicted to   increase   the risk of immunosuppression when given with   dinutuximab .  Manufacturer advises avoid except in life-threatening situations .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709453",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709453_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fludrocortisone\" outputclass=\"int-drug\">Fludrocortisone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of immunosuppression when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid except in life-threatening situations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fludrocortisone   is predicted to   increase   the risk of immunosuppression when given with   dinutuximab .  Manufacturer advises avoid except in life-threatening situations .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709454",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709454_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluticasone\" outputclass=\"int-drug\">Fluticasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of immunosuppression when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid except in life-threatening situations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluticasone   is predicted to   increase   the risk of immunosuppression when given with   dinutuximab .  Manufacturer advises avoid except in life-threatening situations .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluticasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709455",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709455_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hepatitis B immunoglobulin\" outputclass=\"int-drug\">Hepatitis B immunoglobulin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">alter</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hepatitis B immunoglobulin   is predicted to   alter   the effects of   dinutuximab .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hepatitis B immunoglobulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709456",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709456_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrocortisone\" outputclass=\"int-drug\">Hydrocortisone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of immunosuppression when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid except in life-threatening situations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydrocortisone   is predicted to   increase   the risk of immunosuppression when given with   dinutuximab .  Manufacturer advises avoid except in life-threatening situations .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709457",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709457_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"influenza vaccine (live)\" outputclass=\"int-drug\">Influenza vaccine (live)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Influenza vaccine (live)   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   dinutuximab .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Influenza vaccine (live)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709458",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709458_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"measles, mumps and rubella vaccine, live\" outputclass=\"int-drug\">Measles, mumps and rubella vaccine, live</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Measles, mumps and rubella vaccine, live   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   dinutuximab .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Measles, mumps and rubella vaccine, live</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709459",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709459_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"methylprednisolone\" outputclass=\"int-drug\">Methylprednisolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of immunosuppression when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid except in life-threatening situations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Methylprednisolone   is predicted to   increase   the risk of immunosuppression when given with   dinutuximab .  Manufacturer advises avoid except in life-threatening situations .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylprednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709460",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709460_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mometasone\" outputclass=\"int-drug\">Mometasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of immunosuppression when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid except in life-threatening situations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mometasone   is predicted to   increase   the risk of immunosuppression when given with   dinutuximab .  Manufacturer advises avoid except in life-threatening situations .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709461",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709461_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"normal immunoglobulin\" outputclass=\"int-drug\">Normal immunoglobulin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">alter</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Normal immunoglobulin   is predicted to   alter   the effects of   dinutuximab .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Normal immunoglobulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709462",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709462_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"prednisolone\" outputclass=\"int-drug\">Prednisolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of immunosuppression when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid except in life-threatening situations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Prednisolone   is predicted to   increase   the risk of immunosuppression when given with   dinutuximab .  Manufacturer advises avoid except in life-threatening situations .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709463",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709463_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rabies immunoglobulin\" outputclass=\"int-drug\">Rabies immunoglobulin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">alter</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rabies immunoglobulin   is predicted to   alter   the effects of   dinutuximab .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rabies immunoglobulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709464",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709464_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rotavirus vaccine\" outputclass=\"int-drug\">Rotavirus vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rotavirus vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   dinutuximab .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rotavirus vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709465",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709465_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tetanus immunoglobulin\" outputclass=\"int-drug\">Tetanus immunoglobulin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">alter</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tetanus immunoglobulin   is predicted to   alter   the effects of   dinutuximab .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetanus immunoglobulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709466",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709466_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"triamcinolone\" outputclass=\"int-drug\">Triamcinolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of immunosuppression when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid except in life-threatening situations</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Triamcinolone   is predicted to   increase   the risk of immunosuppression when given with   dinutuximab .  Manufacturer advises avoid except in life-threatening situations .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamcinolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709467",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709467_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"typhoid vaccine, oral\" outputclass=\"int-drug\">Typhoid vaccine, oral</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Typhoid vaccine, oral   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   dinutuximab .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Typhoid vaccine, oral</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709468",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709468_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"varicella-zoster immunoglobulin\" outputclass=\"int-drug\">Varicella-zoster immunoglobulin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">alter</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Varicella-zoster immunoglobulin   is predicted to   alter   the effects of   dinutuximab .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Varicella-zoster immunoglobulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709469",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709469_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"varicella-zoster vaccine\" outputclass=\"int-drug\">Varicella-zoster vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Varicella-zoster vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   dinutuximab .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Varicella-zoster vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709470",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dinutuximab#bnf_i1557280709470_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"yellow fever vaccine, live\" outputclass=\"int-drug\">Yellow fever vaccine, live</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"dinutuximab\" outputclass=\"int-heading-drug\">dinutuximab</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Yellow fever vaccine, live   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   dinutuximab .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Yellow fever vaccine, live</title>"
					}
				}
			],
			"hasSearchLabel": " Dinutuximab  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/dinutuximab.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Dinutuximab </title>"
			},
			"rdfs:label": "dinutuximab"
		}
	]
}